Perinatal Depression
Conditions
Brief summary
The study aims at identifying: 1. specific biological and molecular alterations associated with development of depression in pregnancy or risk of it. 2. specific biological and molecular alterations due to exposure to maternal depression in utero that are still present in the offspring, that could possibly mediate the development of negative outcomes, and which are the possible clinical moderators of the associated risk; 3. whether antidepressant therapies prescribed by personal physician and the use of digital tools can have a preventive effect in the transmission of the risk from mothers to babies and in the development of depressive symptoms in high-risk pregnant women; In order to achieve these, 80 pregnant women with depression, 80 at high-risk and 80 controls will be recruited and clinically monitored over pregnancy and postpartum along with their babies, specifically at these timepoints: 25th and 32nd weeks of gestation, 1 week postpartum, 4 weeks postpartum, 8 weeks postpartum, 12 months postpartum. Women, based on their clinician choice, will receive antidepressants and will be provided with a smartphone app to monitor them, using a combination of personalised, daily self-reported assessments and sensors for passive data collection to cover mental and physical health. Blood and saliva samples from pregnant women will be collected at the 25th and 32nd week of gestation to perform biological analyses. Saliva samples from babies will be collected at 8 weeks and 12 months postpartum to perform biological analyses. Clinical and psychological data will be collected from women at all timepoints.
Interventions
PROCEDUREBlood and saliva collection
Blood and saliva samples from pregnant women; saliva samples from babies.
BEHAVIORALPsychometric scales
A battery of psychometric scales and questionnaires.
OTHERSmartphone app
A smartphone application has been developed in the context of the study as a potential preventive and screening strategy.
Sponsors
IRCCS Centro San Giovanni di Dio Fatebenefratelli
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Pregnant women of a singleton pregnancy * Age ≥ 18 years
Exclusion criteria
* Uterine anomalies and obstetric complications * Comorbidity with severe or chronic diseases * Substance abuse * Language barrier
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differentially expressed genes and biological pathways modulation | 25th and 32nd weeks of gestation for pregnant women; 8 weeks and 12 months postpartum for babies. |
Secondary
| Measure | Time frame |
|---|---|
| Rate and profile of DNA methylation | 25th and 32nd weeks of gestation for pregnant women; 8 weeks and 12 months postpartum for babies. |
| Cortisol levels | 25th and 32nd weeks of gestation for pregnant women; 8 weeks and 12 months postpartum for babies. |
| Immune-related factors levels | 25th and 32nd weeks of gestation for pregnant women; 8 weeks and 12 months postpartum for babies. |
| Smartphone app utility | From 25th of gestation to 12 months postpartum |
Countries
Italy
Contacts
Primary ContactAnnamaria Cattaneo
Outcome results
None listed